WallStreetZenWallStreetZen

NASDAQ: UBX
Unity Biotechnology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for UBX

Based on 2 analysts offering 12 month price targets for Unity Biotechnology Inc

Min Forecast
$2.00+150.63%
Avg Forecast
$3.00+275.94%
Max Forecast
$4.00+401.25%

Should I buy or sell UBX stock?

Based on 2 analysts offering ratings for Unity Biotechnology Inc.

Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their UBX stock forecasts and price targets.

UBX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-27
lockedlocked$00.00+00.00%2025-04-23

1 of 1

Forecast return on equity

Is UBX forecast to generate an efficient return?

Forecast return on assets

Is UBX forecast to generate an efficient return on assets?

Company
-14.75%
Industry
32.45%
UBX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

UBX earnings per share forecast

What is UBX's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.09
Avg 2 year Forecast
-$0.80
Avg 3 year Forecast
-$0.52

UBX revenue forecast

What is UBX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$19.9M
Avg 2 year Forecast
$41.7M
Avg 3 year Forecast
$8.1M

UBX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
UBX$0.80$3.00+275.94%Buy
EDSA$1.92$21.00+993.75%Buy
RLYB$0.32$5.00+1,443.21%Buy
MTVA$0.73$7.50+924.59%Strong Buy
ABP$0.22$4.00+1,760.47%Strong Buy
View Top Biotech Stocks

Unity Biotechnology Stock Forecast FAQ

Is Unity Biotechnology Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: UBX) stock is to Buy UBX stock.

Out of 2 analysts, 1 (50%) are recommending UBX as a Strong Buy, 0 (0%) are recommending UBX as a Buy, 1 (50%) are recommending UBX as a Hold, 0 (0%) are recommending UBX as a Sell, and 0 (0%) are recommending UBX as a Strong Sell.

If you're new to stock investing, here's how to buy Unity Biotechnology stock.

What is UBX's earnings growth forecast for 2025-2027?

(NASDAQ: UBX) Unity Biotechnology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Unity Biotechnology's earnings in 2025 is -$27,502,000.On average, 2 Wall Street analysts forecast UBX's earnings for 2025 to be -$18,761,267, with the lowest UBX earnings forecast at -$21,859,458, and the highest UBX earnings forecast at -$15,663,077. On average, 2 Wall Street analysts forecast UBX's earnings for 2026 to be -$13,769,738, with the lowest UBX earnings forecast at -$15,146,711, and the highest UBX earnings forecast at -$12,392,764.

In 2027, UBX is forecast to generate -$8,950,329 in earnings, with the lowest earnings forecast at -$8,950,329 and the highest earnings forecast at -$8,950,329.

What is UBX's revenue growth forecast for 2026-2028?

(NASDAQ: UBX) Unity Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Unity Biotechnology's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast UBX's revenue for 2026 to be $341,661,614, with the lowest UBX revenue forecast at $341,661,614, and the highest UBX revenue forecast at $341,661,614. On average, 1 Wall Street analysts forecast UBX's revenue for 2027 to be $718,436,059, with the lowest UBX revenue forecast at $718,436,059, and the highest UBX revenue forecast at $718,436,059.

In 2028, UBX is forecast to generate $140,107,080 in revenue, with the lowest revenue forecast at $140,107,080 and the highest revenue forecast at $140,107,080.

What is UBX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: UBX) forecast ROA is -14.75%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is UBX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year UBX price target, the average UBX price target is $3.00, with the highest UBX stock price forecast at $4.00 and the lowest UBX stock price forecast at $2.00.

On average, Wall Street analysts predict that Unity Biotechnology's share price could reach $3.00 by May 27, 2026. The average Unity Biotechnology stock price prediction forecasts a potential upside of 275.94% from the current UBX share price of $0.80.

What is UBX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: UBX) Unity Biotechnology's current Earnings Per Share (EPS) is -$1.62. On average, analysts forecast that UBX's EPS will be -$1.09 for 2025, with the lowest EPS forecast at -$1.27, and the highest EPS forecast at -$0.91. On average, analysts forecast that UBX's EPS will be -$0.80 for 2026, with the lowest EPS forecast at -$0.88, and the highest EPS forecast at -$0.72. In 2027, UBX's EPS is forecast to hit -$0.52 (min: -$0.52, max: -$0.52).

What is UBX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: UBX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.